Shockwave therapy, or extracorporeal shockwave therapy (ESWT), has the most direct wrist-tendon evidence in De Quervain tenosynovitis. Recent randomized trials and a 2024 network meta-analysis support it as a noninvasive option for short- and medium-term pain relief. Corticosteroid injection combined with a short period of immobilization remains the established primary treatment, and evidence for shockwave in other wrist tendon problems, such as intersection syndrome and extensor carpi ulnaris (ECU) tendinopathy, is much more limited.
The details matter: which condition was studied, what the comparison was, how long patients were followed and how the shockwave was delivered.
What the current De Quervain evidence shows
2024 network meta-analysis
14 RCTs
ESWT significantly improved short-term pain compared with placebo and ranked highest at that time point
PMID 38613563
2025 randomized trial
60 patients
ESWT and high-intensity laser therapy both improved pain and function through three months
PMID 40270626
Treatment rankings do not establish universal superiority, and protocols differ between studies.
Why the condition has to be identified first
De Quervain tenosynovitis involves the abductor pollicis longus and extensor pollicis brevis tendons in the first dorsal compartment at the radial styloid. Intersection syndrome involves a different location higher on the forearm, where the first and second extensor compartments cross. ECU tendinopathy and ECU instability involve the little-finger side of the wrist. These are different tendons, different anatomy and different problems.
Almost all of the controlled shockwave research on wrist tendons involves De Quervain's. Before the evidence below can be applied, the examination has to establish that De Quervain's is actually the diagnosis. The differences are covered in De Quervain's vs intersection syndrome and ECU tendinopathy vs ECU subluxation.
The 2024 network meta-analysis
A network meta-analysis compares several treatments at once by combining direct comparisons from head-to-head trials with indirect comparisons through shared comparators such as placebo. Chong and colleagues analyzed 14 randomized controlled trials of De Quervain tenosynovitis treatments, published in the Journal of Hand Surgery in 2024 (Chong, 2024).
Short term (up to six weeks): ESWT significantly improved pain on a visual analog scale compared with placebo and ranked highest among the treatments analyzed. Corticosteroid injection combined with casting and laser therapy combined with an orthosis also showed favorable results. Corticosteroid injection alone, platelet-rich plasma alone, acupuncture and an orthosis alone did not differ significantly from placebo at this time point.
Medium term (six weeks to six months): ESWT again ranked highest, followed by corticosteroid injection with casting.
Long term (one year): corticosteroid injection alone and platelet-rich plasma showed sustained pain relief.
Despite the shockwave rankings, the authors concluded that corticosteroid injection with a short period of immobilization remains the primary and effective treatment, and that ESWT can be considered a secondary option.
How to read the rankings
Treatment rankings in a network meta-analysis are probabilistic estimates drawn from direct and indirect comparisons. A top ranking means a treatment was most likely to perform best across the available trials at that time point. It does not prove that the top-ranked treatment is better for every patient, and it can shift as new trials are added. Several comparisons in a network rest on small numbers of trials, and trials differ in patients, protocols and how outcomes were measured.
The authors' own conclusion reflects this. Shockwave ranked well for short- and medium-term pain, while the established treatment remained corticosteroid injection with brief immobilization.
The 2025 randomized trial
Karakuzu Güngör and Güngör randomized 60 patients with De Quervain tenosynovitis to ESWT (29 patients) or high-intensity laser therapy (HILT, 31 patients). Mean age was 43.3 years, with participants aged 18 to 65 (Karakuzu Güngör, 2025).
Outcomes included pain at rest and with movement, the QuickDASH questionnaire for arm, shoulder and hand function, pain-free grip strength and pressure-pain threshold, measured at three weeks and three months.
Both groups improved in all measured parameters. HILT showed a higher pressure-pain threshold at three weeks. The authors concluded that both treatments were safe and effective.
This trial supports shockwave as a reasonable De Quervain option, but it did not establish ESWT as superior to the comparison treatment, and HILT showed an advantage in some measures. There was no sham or placebo group, so the trial cannot separate treatment effects from natural recovery or expectation, and follow-up ended at three months.
The shockwave protocol was five sessions at two-day intervals over three weeks, 1,000 pulses per session at 18 to 21 Hz and 1.4 to 1.8 bar on a pneumatic device. The paper did not label the shockwave as radial or focused.
The 2025 hand-surgery systematic review
Al-Mousllie and colleagues reviewed shockwave therapy across hand conditions, including Dupuytren's disease, trigger finger, De Quervain tenosynovitis, osteonecrosis of the lunate and carpal tunnel syndrome (Al-Mousllie, 2025).
For De Quervain's, the review reported improvements in pain and function in the short and medium term, and one included study found local corticosteroid injection and ESWT equally effective. The authors also described the De Quervain evidence base as very slim and recommended that ESWT be considered as an option rather than a replacement for established care.
The 2026 meta-analysis of mixed tenosynovitis
Zhang and colleagues pooled 12 randomized trials with 760 patients in a meta-analysis framed around finger stenosing tenosynovitis (Zhang, 2026). The pooled trials included both trigger finger and De Quervain tenosynovitis, so the results are not De Quervain-specific. Five trials were published in English and seven in Chinese. Comparators included sham shockwave, local block injections, conventional physical therapy and anti-inflammatory medication.
Shockwave was associated with lower pain scores (mean difference −1.32 points; 95% CI −1.85 to −0.79). QuickDASH did not differ significantly (mean difference −6.14; 95% CI −14.00 to 1.72), with high heterogeneity. The Cooney wrist score favored shockwave (mean difference 13.84; 95% CI 5.04 to 22.64), but heterogeneity was very high (I² 95%).
Mixing diagnoses and comparators makes this analysis useful as supporting context, not as a direct estimate of how shockwave performs in De Quervain's alone.
How corticosteroid injection and immobilization fit
Corticosteroid injection combined with immobilization remains established De Quervain care. A 2024 systematic review and meta-analysis of 16 studies with 1,206 patients found that injection produced higher treatment success than immobilization alone (risk ratio 1.61; 95% CI 1.21 to 2.15). Injection combined with immobilization outperformed immobilization alone (risk ratio 2.15; 95% CI 1.77 to 2.62) and injection alone (risk ratio 1.23; 95% CI 1.12 to 1.34). The authors recommended injection as first-line treatment, with immobilization as an adjunct (Cevik, 2024).
Shockwave does not replace that evidence. It is an additional noninvasive option for patients who prefer to avoid or delay injection, who have not responded to an initial program, or for whom injection is not suitable, after that choice is discussed openly with them.
What about broader tendinopathy evidence?
A 2026 systematic review compared shockwave with therapeutic ultrasound across tendinopathies in 14 randomized trials and 639 patients, all judged to be at high risk of bias (Dudoń, 2026). In lateral epicondylitis, very-low-certainty evidence favored shockwave for rest pain (mean difference −1.51; 95% CI −2.71 to −0.31), with high heterogeneity, while elbow function scores did not differ.
Broader tendinopathy research helps explain why shockwave is studied in tendon disorders, but it does not substitute for condition-specific trials at the wrist.
Intersection syndrome and ECU: what the evidence does not show
We did not find controlled shockwave trials in intersection syndrome or ECU tendinopathy. De Quervain shockwave results should not be transferred to either condition. Intersection syndrome involves friction at a tendon crossover higher on the forearm. ECU tendinopathy involves a different tendon on the opposite side of the wrist.
ECU instability is never a shockwave indication. A tendon that slips out of its groove has a mechanical containment problem, and shockwave does not change that mechanics.
When shockwave is considered for stable ECU tendinopathy or persistent intersection syndrome, it is a clinical judgment based on general tendinopathy principles, explained to the patient as such, not a claim of proven benefit.
Radial or focused shockwave?
The modality question matters, but the wrist evidence does not answer it. The 2024 network meta-analysis did not separate results by shockwave type. The 2025 randomized trial reported pressure in bar on a pneumatic device without labeling it radial or focused, and the reviews pooled varied protocols. No De Quervain trial in this summary compared radial and focused shockwave directly.
Protocols differ between studies
Session number, interval, pulse count, frequency, energy or pressure, probe placement and the use of anesthesia or co-interventions vary across trials. Outcome timing ranges from a few weeks to a year. This heterogeneity is one reason pooled estimates are uncertain and why a positive result from one protocol should not be assumed for another.
For patients, the practical point is that a study's protocol describes what was tested, not a universal prescription. A treatment plan is set from the diagnosis, the stage of symptoms and how the tendon responds over the first sessions.
Key studies at a glance
| Study | Year | Design | Population | n | ESWT modality | Comparator | Sessions | Follow-up | Pain result | Function result | Key limitation |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chong et al. | 2024 | Network meta-analysis | De Quervain tenosynovitis | 14 RCTs | Not specified | Placebo, injection, casting, orthosis, laser, PRP, acupuncture | Varied by trial | Up to 1 year | ESWT ranked highest at short and medium term | Rankings based on pain | Rankings are probabilistic; protocols differ |
| Karakuzu Güngör and Güngör | 2025 | Randomized trial | De Quervain tenosynovitis, ages 18 to 65 | 60 | ESWT, type not specified (bar parameters) | High-intensity laser | 5 over 3 weeks | 3 months | Both groups improved | Both improved QuickDASH and grip | No sham group; short follow-up |
| Al-Mousllie et al. | 2025 | Systematic review | Hand conditions including De Quervain’s | Not pooled | Varied | Varied, including injection | Varied | Short to medium term | Improved | Improved | De Quervain evidence described as very slim |
| Zhang et al. | 2026 | Meta-analysis | Trigger finger and De Quervain’s combined | 12 RCTs, 760 | Varied | Sham, block injection, physical therapy, NSAIDs | Varied | Varied | Lower pain scores | QuickDASH not significant; Cooney score improved | Mixed diagnoses; high heterogeneity |
| Dudoń and Stania | 2026 | Systematic review | Tendinopathies, not wrist-specific | 14 RCTs, 639 | Varied | Therapeutic ultrasound | Varied | Varied | Rest pain favored ESWT in lateral epicondylitis | Elbow function not different | Very low certainty; high risk of bias |
Where manual therapy and bracing fit
Manual soft-tissue treatment of the forearm muscles can be used as an adjunct when the examination finds restricted or tender muscle around the involved tendons. It is not a standalone treatment for tenosynovitis and does not replace loading, splinting or injection when those are indicated.
Bracing is diagnosis-specific. A thumb spica splint immobilizes the first compartment for De Quervain's and has a defined role alongside injection. Intersection syndrome may also be splinted early. ECU instability calls for protection from the position that displaces the tendon, which is a different goal from resting an irritated tendon.
Who may be a candidate
Shockwave may be reasonable for a patient with a confirmed De Quervain diagnosis whose symptoms persist despite load modification and a splinting and loading program, who prefers a noninvasive option, or who cannot have or does not want an injection. It is not a first step for undiagnosed wrist pain.
Fracture, suspected infection, inflammatory arthritis, progressive numbness and tendon rupture need appropriate assessment before any tendon-directed treatment.
The bottom line
Shockwave therapy has meaningful randomized-trial and meta-analytic support as a noninvasive option for De Quervain tenosynovitis, particularly for short- and medium-term pain. Corticosteroid injection with brief immobilization remains the established primary treatment, and rankings from the network meta-analysis do not mean shockwave is better for every patient. Evidence for other wrist tendon problems is limited, and ECU instability is not a shockwave indication.
At Novo, we confirm the diagnosis first and then discuss shockwave alongside other options when the evidence and the exam support it. See how we approach wrist and forearm tendon pain, or read more about shockwave therapy.
References
- Chong HH, Pradhan A, Dhingra M, Liong W, Hau MYT, Shah R. Advancements in de Quervain tenosynovitis management: a comprehensive network meta-analysis. Journal of Hand Surgery (American Volume). 2024;49(6):557-569. PMID 38613563. (link)
- Karakuzu Güngör Z, Güngör E. The comparison of the efficacy of extracorporeal shockwave therapy and high-intensity laser therapy in the treatment of de Quervain tenosynovitis. Turkish Journal of Physical Medicine and Rehabilitation. 2025;71(1):28-36. PMID 40270626. (link)
- Al-Mousllie I, Vogt PM, Jokuszies A. State of shock: a systematic review of extracorporeal shockwave therapy in hand surgery. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW. 2025;14:Doc03. PMID 41602486. (link)
- Zhang L, Luo Y, Chen L, Zhang X, Chen J. Extracorporeal shockwaves therapy for finger stenosing tenosynovitis: a systematic review and meta-analysis. Frontiers in Physiology. 2026;17:1714817. PMID 41727952. (link)
- Cevik J, Keating N, Hornby A, Salehi O, Seth I, Rozen WM. Corticosteroid injection versus immobilisation for the treatment of De Quervain's tenosynovitis: a systematic review and meta-analysis. Hand Surgery and Rehabilitation. 2024;43(3):101694. PMID 38642740. (link)
- Dudoń A, Stania M. Shockwave or ultrasound therapy for tendinopathy: a systematic review and meta-analysis. Journal of Clinical Medicine. 2026;15(5):2007. PMID 41827423. (link)
